

CMG projekt Hevylite u AMM

- **Cíl: zhodnocení významu stanovení Hevylite® pro stanovení prognózy AMM (= imunoparéza)**
- **Trvání projektu: 2 roky**
- **Sponzoring: The Binding Site, UK**

Plán projektu:

- 1/ retrospektivní pilotní projekt**
 - banka vzorků + údaje z RMG**
- 2/ prospektivní sledování a sběr vzorků od nově diagnostikovaných nemocných s AMM**

THE IMPORTANCE OF IMMUNOPARESIS ASSESSMENT IN PATIENTS WITH ASYMPTOMATIC MULTIPLE MYELOMA - FIRST RESULTS OF A NEW CMG PROJECT.

Maisnar V., Pour L., Pika T., Straub J., Walterova L., Gregora E., Machalkova K., Adam Z., Scudla V., Jarkovsky J., Hajek R.

Czech Myeloma Group, CZECH Republic


Introduction: Exploring new prognostic factors is important theme in patients with multiple myeloma (MM). The goal is to find simple laboratory examinations that would allow the identification of patients with varying degrees of the risk of transition to symptomatic form. Such tests include immunoparesis determination, which can be assessed through examination concentrations of polyclonal immunoglobulin (Ig) or newly determine the degree of suppression of an alternative pair of monoclonal immunoglobulin (MIG) using the method HevyLite™.

Methods: Report analyzed in this pilot study included 71 serum samples of patients with asymptomatic MM (34 men and 37 women; 51 patients with IgG and 20 patients with IgA MIG type). For determination of the concentration of heavy/light chain immunoglobulin pairs and then for assessment of the immunoparesis degree was used HevyLite™ method on turbidimeter SPA Plus platform. The project is supported by The BindingSite research grant. Statistical results and basic parameters analyzed patients from the CMG registry ensure Institute of biostatistics and analysis by Faculty of Medicine MU Brno.

Results: Of the 71 patients occurred during the processing of the results already in 32 (45,1%) disease progression to symptomatic forms. HevyLite™ method were statistically significantly associated with the risk of progression only in patients with IgG MIG type, in this group of patients was found prognostic value higher ($p = 0.006$) than for the immunoparesis assessment using polyclonal Ig ($p = 0.017$). Conversely, in patients with IgA type MIG when using methods HevyLite™ no statistically significant relationship was proved.

Conclusions: Assessing the degree of immunoparesis is an important prognostic factor in MM, which is part of the new staging systems of asymptomatic MM. The results of our pilot study confirmed the value of HevyLite™ method as a new tool for immunoparesis assessment till now only in patients with IgG MIG type.

Výsledky analýzy TTP – IgG typ



Závěrečné shrnutí výsledků pilotní fáze CMG projektu Hevylite

- posouzení imunoparézy patří k významným prognostickým faktorům asymptomatického MM
 - součást prognostických systémů (i CMG)
 - dříve polyklonální Ig x nově míra suprese alternativního páru stanovená Hevylite®
- výsledky pilotní fáze CMG projektu Hevylite potvrdily význam u nemocných s IgG typem !
- k definitivnímu závěru nutné ↑počty IgA MM